← Back to Search

Drug-Eluting Stent

Bifurcation Cohort for Coronary Artery Disease

N/A

Waitlist Available

Research Sponsored by Medtronic Vascular

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial is to observe the continued performance of the Medtronic Resolute Onyx Stent in a real-world population with bifurcated lesions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Target Vessel Failure (TVF)

Secondary outcome measures

Number of Participants With Cardiac Death

Number of Participants With Cardiac Death and TVMI

Number of Participants With Major Adverse Cardiac Event (MACE)

+5 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Bifurcation CohortExperimental Treatment1 Intervention

Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System

2018

N/A

~630

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Medtronic VascularLead Sponsor

65 Previous Clinical Trials

56,057 Total Patients Enrolled

40 Trials studying Coronary Artery Disease

43,769 Patients Enrolled for Coronary Artery Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there many health care institutions executing this clinical experiment in the municipality?

"Potential participants are able to enroll in this medical trial at 23 different locations, including Abbott Northwestern Hospital (Minneapolis), Mercy Hospital (Coon Rapids) and Nebraska Medical Center (Omaha)."

Answered by AI

What aims does this experiment hope to accomplish?

"As reported by the study sponsor, Medtronic Vascular, this trial's main objective is to measure Number of Participants With Target Vessel Failure (TVF) over a 12 Month period. Additionally, they will be assessing secondary outcomes such as Target Vessel Revascularization (TVR), Cardiac Death and Target Lesion Revascularization (TLR)."

Answered by AI

Is enrollment to this trial still available for individuals?

"Clinicaltrials.gov states that this trial, which first appeared on May 14th 2018 and was last edited October 10th 2022, is not actively seeking participants. Nevertheless, there are 546 other clinical trials currently in need of patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)

2018. "RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03584464.